SI-BONE, Inc. (NASDAQ:SIBN) is one of the stocks Jim Cramer shared his takes on. A caller asked about the company during the ...

Bank of America Securities analyst Craig Bijou reiterated a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $21.00. Craig Bijou has given his Buy rating due to a ...

SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax obligations.

SI-BONE reports strong revenue growth and improved financial metrics for Q4 2024 and FY 2024, achieving positive adjusted EBITDA. SI-BONE, Inc. reported strong financial results for the fourth quarter ...

SI-BONE, Inc., a company focused on medical technologies for sacropelvic disorders, announced it will release its financial results for the fourth quarter and full year of 2024 on February 24, 2025, ...

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you ...

SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be ...

Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective ...

SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth ...

Canaccord Genuity analyst Caitlin Cronin maintained a Buy rating on SI-Bone today and set a price target of $27.00. According to TipRanks, Cronin is a 4-star analyst with an average return of 15.7% ...

Si-Bone makes the iFuse Implant System for the sacroiliac joint, found in the lower back. The company said it increased its surgeon base to 950 surgeons in the U.S. Revenue for Si-Bone was up 46% year ...